UK damages award could chill use of injunctions in infringement cases
This article was originally published in SRA
Before applying for an interim injunction in the UK, pharmaceutical companies may want to take note of a recent Court of Appeal ruling that upheld a £27m damages award made to Krka and Consilient in compensation for delays to the launch of their generic version of AstraZeneca's Nexium (esomeprazole).
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.
A number of countries are resorting to extreme measures such as export bans to preserve stocks of medicines for the COVID-19 pandemic. Belgium is among the latest to impose an export prohibition, but might it fall foul of the EU’s export regulations?